KR20230034320A - 프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법 - Google Patents

프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법 Download PDF

Info

Publication number
KR20230034320A
KR20230034320A KR1020237003002A KR20237003002A KR20230034320A KR 20230034320 A KR20230034320 A KR 20230034320A KR 1020237003002 A KR1020237003002 A KR 1020237003002A KR 20237003002 A KR20237003002 A KR 20237003002A KR 20230034320 A KR20230034320 A KR 20230034320A
Authority
KR
South Korea
Prior art keywords
wild
residue
type human
position corresponding
human neu2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003002A
Other languages
English (en)
Korean (ko)
Inventor
리 펑
산딥 에이. 셸케
리즈 차오
Original Assignee
팔레온 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팔레온 파마슈티칼스 인크. filed Critical 팔레온 파마슈티칼스 인크.
Publication of KR20230034320A publication Critical patent/KR20230034320A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237003002A 2020-07-03 2021-07-02 프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법 Pending KR20230034320A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047989P 2020-07-03 2020-07-03
US63/047,989 2020-07-03
US202163134411P 2021-01-06 2021-01-06
US63/134,411 2021-01-06
PCT/US2021/040240 WO2022006492A2 (en) 2020-07-03 2021-07-02 Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same

Publications (1)

Publication Number Publication Date
KR20230034320A true KR20230034320A (ko) 2023-03-09

Family

ID=79317685

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003002A Pending KR20230034320A (ko) 2020-07-03 2021-07-02 프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법

Country Status (11)

Country Link
US (1) US20230265406A1 (https=)
EP (1) EP4176056A4 (https=)
JP (1) JP2023532021A (https=)
KR (1) KR20230034320A (https=)
CN (1) CN115803047A (https=)
AU (1) AU2021299565A1 (https=)
BR (1) BR112022026720A2 (https=)
CA (1) CA3173145A1 (https=)
IL (1) IL299559A (https=)
MX (1) MX2023000243A (https=)
WO (1) WO2022006492A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102914621B1 (ko) 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
WO2022150516A1 (en) * 2021-01-06 2022-07-14 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
JP2026509243A (ja) * 2023-03-10 2026-03-17 ジェネンテック， インコーポレイテッド プロテアーゼとの融合およびその使用
WO2025217138A1 (en) * 2024-04-09 2025-10-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6198807B2 (ja) * 2012-03-16 2017-09-20 ジェネンテック， インコーポレイテッド 操作され立体構造的に安定化されたタンパク質
WO2016056913A1 (en) * 2014-10-10 2016-04-14 Enzypep B.V. Peptide fragment condensation and cyclisation using a subtilisin variant with improved synthesis over hydrolysis ratio
WO2017210445A1 (en) * 2016-06-03 2017-12-07 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR102914621B1 (ko) * 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
WO2022150516A1 (en) * 2021-01-06 2022-07-14 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
US20240067729A1 (en) * 2021-01-06 2024-02-29 Palleon Pharmaceuticals Inc. Anti-pd-l1 antibodies and fusion proteins thereof

Also Published As

Publication number Publication date
EP4176056A4 (en) 2024-10-30
CN115803047A (zh) 2023-03-14
WO2022006492A2 (en) 2022-01-06
JP2023532021A (ja) 2023-07-26
EP4176056A2 (en) 2023-05-10
WO2022006492A3 (en) 2022-02-17
US20230265406A1 (en) 2023-08-24
BR112022026720A2 (pt) 2023-01-24
AU2021299565A1 (en) 2023-02-02
IL299559A (en) 2023-02-01
CA3173145A1 (en) 2022-01-06
MX2023000243A (es) 2023-03-03

Similar Documents

Publication Publication Date Title
KR102914621B1 (ko) 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
JP7657249B2 (ja) 治療用ヌクレアーゼ組成物および方法
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
CN109311973B (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
KR20230034320A (ko) 프로테아제 민감도가 감소된 재조합 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법
CN109705218B (zh) Asgpr抗体及其用途
KR20220032576A (ko) 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법
CN107207604B (zh) 抗alk2抗体
CN110234662A (zh) 组织特异性wnt信号增强分子和其用途
KR20230131236A (ko) 항-pd-l1 항체 및 이의 융합 단백질
KR20230138473A (ko) 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
KR20220034812A (ko) 재조합 시알리다제 및 그의 사용 방법
KR20230142722A (ko) 시알리다제-pd-1-항체 융합 단백질들 및 이의 사용방법
CN100515496C (zh) 免疫调节剂及其应用
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer
HK40007646A (en) Asgpr antibodies and uses thereof
HK40007646B (en) Asgpr antibodies and uses thereof
HK40003984B (en) C-terminally fused tnf family ligand trimer-containing antigen binding molecules
HK40003984A (en) C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240702

Comment text: Request for Examination of Application